- Home
- CLDX vs AKRO Comparison
CLDX vs AKRO Comparison
Compare CLDX & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDX
- AKRO
- Stock Information
- Founded
- CLDX 1983
- AKRO 2017
- Country
- CLDX United States
- AKRO United States
- Employees
- CLDX N/A
- AKRO N/A
- Industry
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- CLDX Health Care
- AKRO Health Care
- Exchange
- CLDX Nasdaq
- AKRO Nasdaq
- Market Cap
- CLDX 1.7B
- AKRO 1.8B
- IPO Year
- CLDX 2008
- AKRO 2019
- Fundamental
- Price
- CLDX $20.14
- AKRO $44.86
- Analyst Decision
- CLDX Buy
- AKRO Strong Buy
- Analyst Count
- CLDX 7
- AKRO 9
- Target Price
- CLDX $55.67
- AKRO $76.29
- AVG Volume (30 Days)
- CLDX 714.4K
- AKRO 882.4K
- Earning Date
- CLDX 05-05-2025
- AKRO 05-09-2025
- Dividend Yield
- CLDX N/A
- AKRO N/A
- EPS Growth
- CLDX N/A
- AKRO N/A
- EPS
- CLDX N/A
- AKRO N/A
- Revenue
- CLDX $7,020,000.00
- AKRO N/A
- Revenue This Year
- CLDX N/A
- AKRO N/A
- Revenue Next Year
- CLDX $27.01
- AKRO N/A
- P/E Ratio
- CLDX N/A
- AKRO N/A
- Revenue Growth
- CLDX 1.99
- AKRO N/A
- 52 Week Low
- CLDX $18.61
- AKRO $17.86
- 52 Week High
- CLDX $47.00
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- CLDX 41.83
- AKRO 48.72
- Support Level
- CLDX $18.95
- AKRO $41.15
- Resistance Level
- CLDX $21.85
- AKRO $47.11
- Average True Range (ATR)
- CLDX 1.39
- AKRO 2.32
- MACD
- CLDX 0.08
- AKRO -0.82
- Stochastic Oscillator
- CLDX 38.64
- AKRO 33.64
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.